OTCMKTS:DSNKY Daiichi Sankyo Q4 2025 Earnings Results & Report $17.68 -0.54 (-2.96%) As of 11/10/2026 03:58 PM Eastern Daiichi Sankyo reported Q4 2025 earnings on April 25, 2025. The company reported EPS of $0.30, while revenue was $3.40 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 25, 2025TimeBefore Market Opens Daiichi Sankyo EPS ResultsActual EPS$0.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersDaiichi Sankyo Revenue ResultsActual Revenue$3.40 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDaiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Daiichi Sankyo Q4 2025 Earnings FAQ Did Daiichi Sankyo beat earnings estimates for Q4 2025? Daiichi Sankyo (OTCMKTS:DSNKY) reported earnings of $0.30 per share for Q4 2025. The report was announced on Friday, April 25, 2025. What was Daiichi Sankyo's revenue for Q4 2025? Daiichi Sankyo reported revenue of $3.40 billion for Q4 2025. When is Daiichi Sankyo's next earnings date? Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Daiichi Sankyo on the company's earnings history page. Daiichi Sankyo Earnings HeadlinesIDEL, Daiichi Sankyo Team Up To Test Multi-Drug Conjugate For Solid TumorsNovember 9 at 10:03 AM | rttnews.comDaiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Earnings BeatNovember 4, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 11 at 1:00 AM | Weiss Ratings (Ad)Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call TranscriptOctober 30, 2026 | seekingalpha.comDaiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial ResultsOctober 29, 2026 | businesswire.comDaiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call TranscriptOctober 6, 2026 | seekingalpha.comSee More Daiichi Sankyo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email. Email Address About Daiichi SankyoDaiichi Sankyo (OTCMKTS:DSNKY) is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib). Daiichi Sankyo also invests in research and development, including antibody-drug conjugates and other targeted therapies. Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets, including the United States and Europe. It works with partners in some markets to develop and commercialize medicines.View Daiichi Sankyo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
